Inspire Pharmaceuticals Inc.

Christy L. Shaffer, Ph.D. has served as our Chief Executive Officer and as a director since January 1999, as our President since June 2005, and as a member of our Development Committee since March 2009. Dr. Shaffer joined us in 1995 as the first full-time employee and held several senior positions prior to being appointed our Chief Executive Officer. Dr. Shaffer has over 20 years of experience in drug development within the pharmaceutical industry. She previously served in a variety of positions in the clinical research division of Burroughs Wellcome Co. including International Project Leader for cardiopulmonary programs. She served as the Associate Director of pulmonary research in the department of pulmonary/critical care medicine at Burroughs Wellcome immediately prior to joining Inspire. Dr. Shaffer coordinated several IND submissions and one NDA submission at Burroughs Wellcome. Dr. Shaffer received a Ph.D. in pharmacology from the University of Tennessee and completed two years of postdoctoral training in cardiovascular research in the Biochemistry Department at the Chicago Medical School before her one-year postdoctoral appointment at the University of North Carolina at Chapel Hill.

Benjamin R. Yerxa, Ph.D. has served as our Chief, Scientific Operations and Alliances since December 2005. Prior to that, he held the position of Senior Vice President, Discovery since March 2003. Dr. Yerxa joined Inspire in August 1995 and has held several positions, including Vice President, Discovery and Senior Director of Preclinical Programs. Dr. Yerxa created a novel strategic opportunity for Inspire by developing the concept of ophthalmic uses for Inspire s core P2Y2 technology. As a Senior Research Chemist his work focused on designing and synthesizing novel P2Y receptor agonists, such as diquafosol. While in chemistry, he was the preclinical project leader for diquafosol. In 2004, Dr. Yerxa received the Southeastern Region American Chemical Society (ACS) Industrial Innovation Award for discoveries related to his work with P2Y2 receptors. Dr. Yerxa received the Triangle Business Journal s 40 under 40 award, recognizing his contributions in business and leadership. He was also a finalist for Ernst & Young s Entrepreneur of the Year in NC 2003. Prior to joining Inspire, Dr. Yerxa was a Research Scientist at Burroughs Wellcome. Dr. Yerxa also worked at Biophysica, Inc. where he synthesized radiocontrast agents. He developed scale-up procedures for the industrial production of Oxilan, a marketed imaging product. Dr. Yerxa received a B.A. in Chemistry from the University of California, San Diego, and a Ph.D. in Organic Chemistry from the University of California, Irvine.

Joseph K. Schachle has served as our Executive Vice President and Chief, Commercial and Corporate Operations since August 2007. He previously served as our Executive Vice President and Chief, Commercial Operations from February 2007 until August 2007. Prior to that, he served as Senior Vice President, Marketing and Sales from January 2004 until February 2007 and as Vice President, Marketing and Sales from January 2003 until January 2004. In his current capacity, he is responsible for establishing a marketing and sales infrastructure in North America to commercialize AzaSite®, to promote Elestat® and to commercialize potential products from our pipeline. Mr. Schachle has over 19 years experience in pharmaceutical marketing and sales, and has had responsibility for the successful launch of major new products including the marketing of GlaxoSmithKline' s Advair®. His experience includes marketing and sales positions of significant responsibility at The Upjohn Company, GlaxoSmithKline, Inspire and MedImmune, Inc. Prior to joining Inspire, he most recently served as Director of Marketing for infectious disease products at MedImmune from April 2002 until January 2003, where he was responsible for strategic brand management and promotion of Synagis® and Cytogam®. From June 1998 until April 2001, Mr. Schachle was Director, Marketing for GlaxoSmithKline. Mr. Schachle originally joined Inspire in April 2001 as Vice President, Marketing and Sales. Mr. Schachle holds a B.B.A. in Marketing from James Madison University and an M.B.A. from Old Dominion University.

R. Kim Brazzell, Ph.D. joined Inspire in August 2004 as Senior Vice President of Ophthlamic Research and Development (R&D) where he oversees various aspects of preclinical and clinical R&D, provides strategic direction and expertise to project teams, assists the marketing and sales team in Phase 4 clinical trials and marketing plans and activities, and serves an important external role in further developing Inspire s presence and depth in ophthalmology. Dr. Brazzell has 20 years of experience in the ophthalmic pharmaceutical industry. Prior to joining Inspire, he served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics from 2000 until 2004. He has extensive experience in the discovery and development of multiple successful ophthalmic products including Visudyne , Zaditor , Rescula and Betoptic S . In addition to managing the global clinical R&D group for Novartis Ophthalmics, Dr. Brazzell built and managed the U.S.-based R&D group for Ciba Vision Ophthalmics in Duluth, Georgia, while serving as their Vice-President, R&D, and served as Associate Director, R&D at Alcon Laboratories in Fort Worth, Texas. Dr. Brazzell also has expertise in pharmacokinetics and biopharmaceutics and held positions directing groups in these areas at Alcon Laboratories and Hoffmann-La Roche, where he managed activities across several therapeutic areas including cardiovascular, pulmonary and ophthalmology. Dr. Brazzell received a B.S in Pharmacy and Ph.D. in Pharmaceutical Sciences from the University of Kentucky. Richard M. Evans, Ph.D. has served as our Vice President, Pharmaceutical Development since June 2000. Dr. Evans joined us in October 1996 and has previously held several positions including Director and Senior Director of Pharmaceutical Development. He is responsible for all activities related to the manufacture,

Joseph M. Spagnardi has served as our Senior Vice President, General Counsel and Secretary since March 2006. In his current role, he oversees the legal and intellectual property departments. He previously served as our Vice President and Deputy General Counsel from May 2005 to March 2006. Prior to joining Inspire, Mr. Spagnardi spent over ten years at GlaxoSmithKline (and its predecessor GlaxoWellcome), most recently as Assistant General Counsel for R&D Business Development Transactions, where he structured and negotiated strategic transactions relating to the development and commercialization of pharmaceutical products, development compounds and novel research technologies. Mr. Spagnardi began his career at the law firm of Winthrop, Stimson, Putnam & Roberts (now Pillsbury Winthrop Shaw Pittman LLP), where his practice focused on multi-national transactions in the M&A and Securities area. Mr. Spagnardi received a J.D. with Honors from the University of North Carolina School of Law and a B.S. in Business Administration cum laude from the University of Delaware.

R. Kim Brazzell, Ph.D. has served as our Executive Vice President and Head, Ophthalmology Business since January 2009. Prior to that he held the position of Senior Vice President of Ophthalmic Research and Development (R&D) from August 2004 until December 2008. In his current capacity, Dr. Brazzell oversees the development and implementation of Commercial, R&D, Business Development, and Legal strategies as they relate to Ophthalmology, to ensure optimal management and growth of this important part of our business. He also serves an important external role in further developing Inspire' s presence and depth in ophthalmology. Dr. Brazzell has 20 years of experience in the ophthalmic pharmaceutical industry. Prior to joining Inspire, he served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics from 2000 until 2004. He has extensive experience in the discovery and development of multiple successful ophthalmic products including Visudyne®, Zaditor®, Rescula® and Betoptic S®. In addition to managing the global clinical R&D group for Novartis Ophthalmics, Dr. Brazzell built and managed the U.S.-based R&D group for Ciba Vision Ophthalmics in Duluth, Georgia, while serving as their Vice-President, R&D, and served as Associate Director, R&D, at Alcon Laboratories, Inc. in Fort Worth, Texas. Dr. Brazzell also has expertise in pharmacokinetics and biopharmaceutics and held positions directing groups in these areas at Alcon Laboratories, Inc. and F. Hoffmann-La Roche Ltd., where he managed activities across several therapeutic areas including cardiovascular, pulmonary and ophthalmology. Dr. Brazzell received a B.S. in Pharmacy and Ph.D. in Pharmaceutical Sciences from the University of Kentucky.

Dr. Peterson has over 15 years of academic and industry experience in vision science. He has served as Vice President of Discovery since December 2005. Prior to this position, as Vice President of Biology, Dr. Peterson supervised Inspire's Biology department (Molecular Pharmacology, Biochemistry and Screening, and Drug Evaluation) and worked with other Discovery functional group leaders to set the strategic direction for Biology. He is also the team leader for the glaucoma (cytoskeletal therapy) project. Prior to joining Inspire, Dr. Peterson was a retinal research scientist at Regeneron Pharmaceuticals. He received his Ph.D. in Biophysics from the Dept of Molecular and Cell Biology and School of Optometry at University of California, Berkeley. He was awarded a research fellowship from the Foundation Fighting Blindness and a National Research Service Award from the National Institute of Health in support of his post-graduate training at U.C. San Francisco and Berkeley. His research has focused primarily on retinal pigment epithelium physiology and retinal disease.

Mr. Boyd joined Inspire in October 2003 as a Regional Sales Director and advanced through a series of progressively responsible sales management and managed care roles to his current position in March of 2008. Since joining Inspire, he has played a key role in building the sales and managed care teams of the organization. Currently, Mr. Boyd is responsible for key opinion leader development within the optometric and ophthalmology field, while working closely with the sales and marketing teams to support their functions. Mr. Boyd has over 13 years of experience in the pharmaceutical and medical device industry. His fields of experience range from ophthalmology, anti-infective, anti-inflammatory, allergy, asthma, gastrointestinal, pulmonary endoscopy and biliary endoscopy. Mr. Boyd previously worked for Boston Scientific and Muro Pharmaceutical before joining Inspire. He holds a Bachelor of Science in Psychology and a Bachelor of Arts in Political Science from the University of Memphis in Memphis, TN.

Mr. Goolsby has more than 20 years of Sales and Commercial Operations leadership experience with a variety of pharmaceutical companies. Most recently, he was Vice President of Commercial Operations for Inspire Pharmaceuticals, where he launched the latest entry into the ocular allergy market. Mr. Goolsby has built sales teams ranging in size from 60 to more than 600, and has been responsible for the sales launch of numerous products in a variety of therapeutic categories, including cardiovascular, respiratory, allergy, pain management, antiviral and antimicrobial. Previously, he was National Sales Director at Biovail Pharmaceuticals, and he held various positions in Commercial Operations at Bausch & Lomb, Boehringer Mannheim, and Boehringer Ingelheim. Mr. Goolsby earned a B.S. in Microbiology from the University of Kentucky where he also conducted post graduate research in infectious disease.

Ms. Anderson joined Inspire in May 2004 and is responsible for overseeing preclinical/nonclinical work to support Inspire Discovery and Development projects. Currently she manages the Drug Evaluation department which is responsible for evaluating new therapeutic targets at the in vivo and ex vivo level as well as preclinical evaluation and safety assessment of potential lead compounds. Ms. Anderson brings over 14 years of experience in the area of toxicology and project management to Inspire. Prior to joining Inspire Ms. Anderson worked for RTI International, a not-for-profit contract research organization, as the manager of the Specialty Toxicology and Pharmacology Program. She served as a toxicology study director and was responsible for managing work in the areas of reproductive and endocrine toxicology, pharmacokinetics and toxicokinetics, and specialized pharmacology and toxicology, including the development of specialized animal models. Ms. Anderson holds a Bachelor of Science degree in Zoology from North Carolina State University.

Jennifer McAlister is the North East Texas sales manager for Inspire Pharmaceuticals. She serves as the administrative director of R.U.4 Children and is a key member of the overseas mission team. Jennifer grew up in Ft. Worth and graduated from Texas A&M University. Jennifer's heart for orphans and her passion to see and experience God's is what lead her to the mission field.

Dr. Dover joined Inspire in March 2006 as a Clinical Research Scientist and was promoted to Director, Ophthalmic Medical Science in May 2008. He currently leads a team of Ophthalmic Medical Scientists, responsible for all medical science liaison functions within ophthalmology. Additionally, he supports the Commercial Operations team via medical information services and sales training. Dr. Dover has 8 years of experience in hospital pharmacy and over 12 years of experience in the pharmaceutical industry providing and managing medical information services. Dr. Dover received a Bachelor of Science in Pharmacy and a Doctor of Pharmacy from the University of North Carolina, Chapel Hill.

Ken is co-founder of Hatteras Venture Partners II and former co-head of the International Life Science Practice at Ernst & Young; He is currently Chairman of Inspire Pharmaceuticals, and a member of the boards of OSI Pharmaceuticals, CV Therapeutics and Pozen.

Kip Frey joined Intersouth in 2000 as a venture partner and has served as a full-time partner since 2003, working with the information technology portfolio. Prior to joining Intersouth, he served as Executive Vice President and General Counsel of Ventana Communications Group, having sold the company in 1994. In 1998, he became President of Accipiter, an Intersouth portfolio company, and sold the company to CMGI, Inc. Later, Mr. Frey was recruited by Intersouth to become the President and CEO of OpenSite Technologies, which was acquired by Siebel Systems. He was Vice President and General Manager of Dynamic Commerce Applications for Siebel until June 2001. Kip is a past chairman of the Council for Entrepreneurial Development and a member of Duke Law School's Board of Visitors. He is an adjunct professor at Duke University's Sanford Institute for Public Policy Studies and has served as a professor of the Practice in Entrepreneurial Management & Law at Duke University, with joint appointments from the Fuqua School of Business and Duke Law School. Kip is a Phi Beta Kappa graduate of the University of Southern California and of Duke Law School, where he served on the Duke Law Journal. He currently serves on the boards of four Intersouth portfolio companies and one publicly-traded prior Intersouth portfolio company, Inspire Pharmaceuticals.

Nancy J. Hutson, Ph.D. was appointed a Director of Endo on March 30, 2009. She retired from Pfizer, Inc. in 2006 after spending 25 years in various research and leadership positions, most recently serving as Senior Vice President, Pfizer Global Research and Development and Director of Pfizer's pharmaceutical R&D site, known as Groton/New London Laboratories. Dr. Hutson's career at Pfizer was marked by progressively demanding jobs, first in the research laboratories, then in strategic staff roles and as global leader of Exploratory Development. In her final role at Pfizer, Dr. Hutson led the Groton/New London Laboratory, which was the largest R&D site of any pharmaceutical company. She led 4,500 colleagues (primarily scientists) and managed a budget in excess of $1 billion. She currently is a director of Cubist Pharmaceuticals, Inc. and Inspire Pharmaceuticals, Inc. and serves on the board of Planned Parenthood of Connecticut. Dr. Hutson owns and operates Standing Stones Farm in Ledyard, CT which is dedicated to supporting the equestrian sport of dressage. Ms. Hutson is a member of Endo's Compensation Committee.

Richard S. Kent, M.D. has served as a director and a member of our Compensation Committee since June 2004. He has also served as the Chairman of our Compensation Committee since September 2004 and as a member of our Development Committee since March 2009. He previously served as a member of our Corporate Governance Committee from June 2004 through March 2009. Dr. Kent is currently a Venture Partner with Intersouth Partners, an early-stage venture capital firm based in the southeast. From 2002 until April 2008, Dr. Kent served as the President and Chief Executive Officer of Serenex, Inc. until its sale to Pfizer, and served as President and Chief Executive Officer of Ardent Pharmaceuticals, Inc. from 2001 until joining Serenex. In total, Dr. Kent has more than 20 years of global pharmaceutical experience, including serving as Senior Vice President, Global Medical Affairs, and Chief Medical Officer of GlaxoSmithKline. Prior to GlaxoSmithKline, Dr. Kent held senior positions at Glaxo Wellcome Inc. and Burroughs Wellcome Co. At Glaxo Wellcome, he was Vice President, U.S. Medical Affairs and Group Medical Director, from 1998 through 2001, in addition to serving on the board of directors of Glaxo Wellcome and other senior level operating committees responsible for directing the development and commercialization of the company's products. Prior to such time, at Burroughs Wellcome, he was International Director of Medical Research. Dr. Kent has supervised dozens of Investigational New Drug Applications and over 20 successful New Drug Applications (and equivalent submissions in Europe and the rest of the world) in a wide range of therapeutic areas including CNS, Antivirals, HIV, Respiratory, Gastrointestinal, Anesthesia/Critical Care, Cardiovascular, and Oncology. Dr. Kent received his undergraduate degree from the University of California, Berkeley and his medical degree from the University of California, San Diego. He completed his medical training at Harvard (Peter Bent Brigham Hospital), Stanford University Medical Center and Duke University Medical Center, and was a member of Duke University's medical faculty. He is board certified in both internal medicine and cardiology.